Dr. Reddy's Prepares Generic Semaglutide Launch in India Targeting $1B GLP-1 Market
Dr. Reddy's Laboratories is poised to launch generic oral and injectable semaglutide in India following regulatory approval, targeting a market projected to exceed $1 billion driven by 100 million diabetics.